European health agencies have warned that the weight-loss drug rimonabant -- marketed as Acomplia, Zimulti, Riobant, Rimoslim and Slimona -- may cause dangerous psychological side effects, including suicidal thoughts.
Rimonabant acts to suppress appetite by blocking receptors in the brain that regulate food intake and help break down sugars and fats. It failed to gain approval for use in the
The drug was approved for sale in the European Union, however, in June 2006. The European Commission approved its use to treat obesity, in combination with diet and exercise, among those at risk of cardiovascular disease or Type 2 diabetes. Sales began in the
The conclusion of this article appears on NewsTarget.com, the independent natural health news source for consumers. This article, along with other related articles and uncensored news on important consumer health topics, can be found at:
Acomplia weight loss drug may cause psychiatric side effects in 10 percent of users
http://www.newstarget.com/022361.html
About NewsTarget
Read by over 500,000 unique readers monthly, NewsTarget is a progressive, independent natural health news site that teaches consumers how to improve their health through foods, herbs, exercise and natural therapies. The site also warns consumers about the dangers of processed foods, pharmaceuticals, chemotherapy, environmental toxins and the failure of government regulators like the FDA.
